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Introduction/Background: 
The Hepatitis C virus (HCV) affects some 150 million people worldwide.  However, unlike 
hepatitis A and B there is no vaccination for HCV and approximately 75% of people exposed to 
HCV develop chronic hepatitis.  In Australia, around 226,700 people live with chronic HCV 
infection costing the government approximately $252 million per year.  Historically, the standard 
approved/licenced treatment for HCV is pegylated interferon with ribavirin.  There are major 
drawbacks with interferon-based therapy including side effects, long duration of therapy, limited 
access and affordability.  Our previous survey of an at-risk population reported HCV treatment 
coverage of only 5%.  
Since April 2013, a new class of interferon-free treatments for chronic HCV is subsidised under the 
Pharmaceutical Benefits Scheme: boceprevir and telaprevir - estimated to cost the Australian 
Government in excess of $220 million over five years.  Other biologic interferon-free therapeutic 
agents are scheduled to enter the Australian market.  Use of small molecule generic pharmaceuticals 
has been advocated as a means of public cost savings.  However, with the new biologic agents, 
generics (biosimilars) may not be feasible or straightforward, due to long patent life; marketing 
exclusivity; and regulatory complexity for these newer products.  
 
Research Question: 
How prepared is Australia for the regulation of biosimilars? 
 
Methodology: 
Exploratory case-study analysis of the regulatory framework for biosimilars in Australia.  The case 
studied was the introduction of biosimilar-epoetin in 2006. 
 
Findings: 
Our current pharmaceutical regulatory framework is grounded in small molecule generics rather 
than biosimilars of innovator biologic therapies or vaccines. When biosimilar-epoetins entered the 
market, misapprehension of the nature of small molecule generics vs. biosimilars resulted in 
significant mortality and morbidity.  Australia’s Therapeutic Goods Administration looks to the 
European Medicines Agency for guidance on regulating biosimilars; however, this contradicts IP 
Australia’s position, which advocates identical approaches to both biosimilars and small molecule 
generics.  Australia’s pharmaceutical regulation is influenced by economic pressure from its major 
trading partners. 
 
Policy Implications: 
Australia requires a consistent approach to the regulation of biosimilars, underpinned by the 
National Medicines Policy (2000): equity of access, safety and quality of pharmaceutical, whilst 
fostering innovation in Australia’s pharmaceutical industry. 
 
 
